Episode Details

Send us Fan Mail

A cancer drug gets FDA approval and the biggest voices in oncology call it a “grand slam.” We’re not here to dunk on new treatments, we’re here to read the chart. Joe Grumbine sits down with Dr. Robert Hoffman, a research scientist who has spent decades studying methionine dependence in cancer, to ask what the trial results actually say about pancreatic cancer survival, progression-free survival, and the real cost of side effects when families are desperate for hope.

From there, we zoom out to the bigger problem: why so many clinicians still respond with “I don’t know about methionine restriction” even though PubMed holds thousands of papers linking cancer and methionine. We talk through the logic of a low methionine diet, why methioninase keeps showing synergy with other therapies in early research, and why combination therapy thinking often beats single-miracle narratives in the real world of cancer care.

We also dig into repurposed drugs, including metformin, and why cancer metabolism and oxidative pathways are showing up in more headlines. Along the way we touch on how scientific paradigms shift, why skepticism gets punished, and why remission should come with vigilance and a plan, not complacency.

If you care about evidence-based cancer support, integrative oncology, and practical ways to stack small advantages, listen now, share this with someone who needs it, and subscribe and leave a review so more patients can find the conversation.

Intro for podcast

information about subscriptions

Support the show

Here is the link for Sunday's 4 pm Pacific time Zoom meeting